← All Research Alliance CORP Iii filings

Research Alliance CORP Iii Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NASDAQ
RACC
Research Alliance CORP Iii
425: Oak Hill Bio and Research Alliance Corp. III Combine
Oak Hill Bio and Research Alliance Corporation III announce a business combination and concurrent financing to advance rugonersen for Angelman syndrome.
NASDAQ
RACC
Research Alliance CORP Iii
425: Angelman Syndrome Drug Trial Failure, Future Hope Discussed
An article discusses the failure of Ultragenyx's Angelman syndrome drug GTX-102, while experts see continued hope in other experimental antisense therapies.
NASDAQ
RACC
Research Alliance CORP Iii
425: Oak Hill Bio Goes Public Via SPAC Merger
Oak Hill Bio merges with Research Alliance Corporation III (SPAC) to fund its Angelman syndrome drug development, aiming for Nasdaq listing.
NASDAQ
RACC
Research Alliance CORP Iii
425: Research Alliance Corp III to Combine with OHB Pediatrics
Research Alliance Corporation III (RACC) has entered into a definitive business combination agreement with OHB Pediatrics Ltd. (Oak Hill Bio) to form a new publicly traded rare disease biotechnology company.